(Q36832755)

English

Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis

scientific article published on May 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

16 August 2017

Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis (English)

1 reference

Europe PubMed Central

16 August 2017

rheumatoid arthritis

1 reference

based on heuristic

inferred from title

11

1 reference

Europe PubMed Central

16 August 2017

object named as

Hector Chinoy

2

0 references

object named as

Meghna Jani

1

0 references

object named as

John D Isaacs

9

0 references

Richard B. Warren

3

object named as

Richard B Warren

1 reference

Europe PubMed Central

16 August 2017

5

object named as

Darren Plant

1 reference

Europe PubMed Central

16 August 2017

7

object named as

Ann W Morgan

1 reference

Europe PubMed Central

16 August 2017

Anthony G Wilson

8

object named as

Anthony G Wilson

1 reference

Europe PubMed Central

16 August 2017

author name string

Christopher E M Griffiths

4

1 reference

Europe PubMed Central

16 August 2017

Bo Fu

6

1 reference

Europe PubMed Central

16 August 2017

KimmeL Hyrich

10

1 reference

Europe PubMed Central

16 August 2017

Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate Collaborators

12

1 reference

Europe PubMed Central

16 August 2017

publication date

1 May 2015

1 reference

Europe PubMed Central

16 August 2017

Arthritis & Rheumatology

1 reference

Europe PubMed Central

16 August 2017

67

1 reference

Europe PubMed Central

16 August 2017

8

1 reference

Europe PubMed Central

16 August 2017

2011-2019

1 reference

Europe PubMed Central

16 August 2017

Impact of inadequate adherence on response to subcutaneously administered anti-tumour necrosis factor drugs: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4843946

29 September 2017

Adalimumab serum levels and antidrug antibodies towards adalimumab in peripheral spondyloarthritis: no association with clinical response to treatment or with disease relapse upon treatment discontinuation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4843946

29 September 2017

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4843946

29 September 2017

The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4843946

29 September 2017

Immunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune-mediated Inflammatory conditions: systematic review and meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4843946

29 September 2017

Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept: a single-centre, cohort study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4843946

29 September 2017

The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4843946

29 September 2017

Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4843946

29 September 2017

Immunogenicity to biologics: mechanisms, prediction and reduction

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4843946

29 September 2017

Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4843946

29 September 2017

Immunoglobulin G4: an odd antibody

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4843946

29 September 2017

Adipocytokines: mediators linking adipose tissue, inflammation and immunity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4843946

29 September 2017

Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4843946

29 September 2017

Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4843946

29 September 2017

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4843946

29 September 2017

Bioequivalence and the immunogenicity of biopharmaceuticals

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4843946

29 September 2017

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4843946

29 September 2017

Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumati

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4843946

29 September 2017

Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4843946

29 September 2017

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4843946

29 September 2017

Lower etanercept levels are associated with high disease activity in ankylosing spondylitis patients at 24 weeks of follow-up

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4843946

5 September 2018

Key findings towards optimising adalimumab treatment: the concentration-effect curve.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4843946

5 September 2018

Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4843946

5 September 2018

Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4843946

5 September 2018

Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4843946

5 September 2018

Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NF B signalling pathways

1 reference

https://api.crossref.org/works/10.1002%2FART.39169

21 January 2018

Assessment of long-term safety and efficacy of etanercept in a 5-year extension study in patients with rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4843946

20 October 2018

Comparison of long-term clinical outcome with etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity

1 reference

https://pubmed.ncbi.nlm.nih.gov/26109489

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab

1 reference

https://pubmed.ncbi.nlm.nih.gov/26109489

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner

1 reference

https://pubmed.ncbi.nlm.nih.gov/26109489

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Influence of antibodies against infliximab and etanercept on the treatment effectiveness of these agents in Japanese patients with rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/26109489

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/26109489

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/26109489

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/26109489

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A novel method for the detection of antibodies to adalimumab in the presence of drug reveals “hidden” immunogenicity in rheumatoid arthritis patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/26109489

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept

1 reference

https://pubmed.ncbi.nlm.nih.gov/26109489

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Is there a need for immunopharmacologic guidance of anti-tumor necrosis factor therapies?

1 reference

https://pubmed.ncbi.nlm.nih.gov/26109489

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Differential effect of drug interference in immunogenicity assays

1 reference

https://pubmed.ncbi.nlm.nih.gov/26109489

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1002/ART.39169

1 reference

Europe PubMed Central

16 August 2017

1 reference

Europe PubMed Central

16 August 2017

1 reference

Europe PubMed Central

16 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36832755&oldid=1747671759"